Unknown OBSERVATIONAL NCT05177666

a Prospective Registration Study for Patients With Advanced Refractory Solid Tumors

Patients With Advanced Refractory Solid Tumors Who Failed Standard Treatments and Matched Individualized Treatment Based on Tumor Molecular Characteristics: a Prospective Registration Study

Sponsor: The University of Hong Kong-Shenzhen Hospital

Conditions Effectiveness Feasibility Safety Targeted Molecular Therapy

Interventions Targeted therapy

Updated 4 times since 2022 Last updated: Dec 14, 2021 Started: Dec 30, 2021 Primary completion: Dec 30, 2023 Completion: Mar 30, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05177666, this observational or N/A phase trial focuses on Effectiveness and Feasibility and remains ongoing. Sponsored by The University of Hong Kong-Shenzhen Hospital, it has been updated 4 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown
Jul 2024 — Sep 2024 [monthly]

Unknown

Status: Unknown Status → Unknown
May 2024 — Jul 2024 [monthly]

Unknown Status

Status: Not Yet Recruiting → Unknown Status
Jan 2022 — May 2024 [monthly]

Not Yet Recruiting

First recorded

Dec 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The University of Hong Kong-Shenzhen Hospital
Tianjin Happy Life Technology Co., Ltd.

Data source: The University of Hong Kong-Shenzhen Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.